Demand and volumenegative · 4 filings
“The $46.4 million decrease was primarily attributable to a decrease in sales in the Eye & Ear Care category, due to a limited ability to supply demand for Clear Eyes .”10-K · May 14, 2026 ↗
Prestige Consumer Healthcare Inc.
PBH
Market read
Prestige Consumer Healthcare Inc.'s move is spreading beyond its market group.
The latest filing evidence is available. 5 of 25 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 2 directly disclosed connections are confirming.
What changed
- Revenue increased 6.5% versus the comparable filing period.
- Operating margin fell 9.0 percentage points.
Company-0.8% todayVolume comparison unavailable
Market group5 of 25 activeBiopharmaceuticals and Care · inactive
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- At least 17 of 25 durable members become active together.
- Capital-flow agreement rises above 55%.
- KKR remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 8 of 25 members or fewer.
Research brief
The story so far
The latest filing evidence is available. 5 of 25 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 2 directly disclosed connections are confirming.
Evidence that supports
- Revenue increased 6.5% versus the comparable filing period.
- Operating cash flow covered net income at 2.43x, improving versus the comparable period.
Evidence that challenges
- Operating margin fell 9.0 percentage points.
- Net income decreased 38.5% versus the comparable filing period.
- Gross margin fell 5.0 percentage points.
What would clarify the read
- At least 17 of 25 durable members become active together.
- Capital-flow agreement rises above 55%.
- KKR remains aligned with the group in the next market snapshot.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations328
Usable filing statements80
Verified relationships6
Evidence supporting the case
- Operating cash flow covered net income at 1.35x in the latest annual period.
- Material customer WMT most recently reported revenue +6.9% year over year.
Evidence challenging the case
- Latest annual revenue changed -4.3% year over year.
- Operating margin changed -1.2 percentage points in the latest annual period.
- Net margin changed -1.4 percentage points in the latest annual period.
- Demand and volume has repeated adverse evidence across 4 filings.
- Restructuring and cost reductions has repeated adverse evidence across 4 filings.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 11, 2026
46.956m-24.2%12m-27.8%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2022-03-31$1.1B+15.2%$4.04+0.5%
2023-03-31$1.1B+3.8%$-1.65-1.9%
2024-03-31$1.1B-0.2%$4.17+0.6%
2025-03-31$1.1B+1.1%$4.29-0.2%
2026-03-31$1.1B-4.3%$3.91-2.7%
What management says matters
Persistent and emerging business drivers
Macroeconomic conditionsmixed · 4 filings
“As a percentage of International OTC Healthcare revenues, gross profit decreased to 54.1% during 2026 from 58.1% during 2025, primarily due to increased inflation as well as channel and product mix.”10-K · May 14, 2026 ↗
Restructuring and cost reductionsnegative · 4 filings
“The decrease in depreciation and amortization expenses was primarily related to a decrease in amortization expense due to impairment charges taken on certain finite-lived brands in fiscal 2025, as well as certain intangible assets being fully amortized during…”10-K · May 14, 2026 ↗
Capital investment and capacitynegative · 1 filings
“The decrease of $2.7 million in net cash used in investing activities was primarily due to a decrease in capital expenditures of $1.3 million and changes in a short-term loan receivable of $1.2 million.”10-K · May 14, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 2.1× · EV/sales 3.0×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
46.95-0.8% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for PBH. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment
The latest filing shows material pressure
10-Q filed 2026-08-06 against the comparable filing from 2025-08-07.
OperationscautiousEvidence score -1
liquidityconstructiveEvidence score +1
valuationmixed
Capital and cash conversion
Investment load increased
Capital spending consumed more revenue while free-cash-flow margin declined.
- Capital spending YoY
- +341.9%
- Capital spending / revenue
- +1.4%
- Free-cash-flow margin
- +25.2%
- FCF margin change
- -6.1 pts
Capex, revenue, and operating cash flow are matched to the same reported duration. Reported accounting context, not a forecast or trading recommendation.
What improved
- Revenue increased 6.5% versus the comparable filing period.
- Operating cash flow covered net income at 2.43x, improving versus the comparable period.
What weakened
- Operating margin fell 9.0 percentage points.
- Net income decreased 38.5% versus the comparable filing period.
- Gross margin fell 5.0 percentage points.
Filing receipts
“The $1,054.7 million increase in cash provided by financing activities was primarily due to the proceeds from the issuance of term loans of $1,045.0 million under the Term Loan Credit Agreement and a decrease in the repurchase of shares of our common stock in conjunction with our share repurchase program of $34.8 million, partly offset by the payment of debt issuance costs of $22.5 million.”
“As a percentage of North American OTC Healthcare revenues, contribution margin decreased to 38.5% during the three months ended June 30, 2026 from 43.0% during the three months ended June 30, 2025, primarily due to the decrease in gross profit margin noted above.”
“The $13.6 million increase was primarily attributable to an increase in sales in the Wellness, Sleep & Other, Gastrointestinal, Dermatological, and Cough, Cold & Allergy categories, partly offset by a decrease in the Women's Health category.”
Historical filing backfill generated after the original filing window. It is not part of Jodie's live track record.
Business ecosystem
The relationships behind PBH
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
WMT20.0% of PBHcustomerMay 14, 2026 ▾
“During 2026, Walmart and Amazon, which accounted for approximately 20% and 15%, respectively, of our gross revenues, were our only customers that accounted for more than 10% of our gross revenues.”
AMZN15.0% of PBHcustomerMay 14, 2026 ▾
“During 2026, Walmart and Amazon, which accounted for approximately 20% and 15%, respectively, of our gross revenues, were our only customers that accounted for more than 10% of our gross revenues.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PBH is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.